Elevated levels of soluble CD163 in sera and fluids from rheumatoid arthritis patients and inhibition of the shedding of CD163 by TIMP-3

Clinical and Experimental Immunology

Volumn 130, Issue 1, 2002, Pages 156-161

  Matsushita, N ^a   Kashiwagi, M ^b   Wait, R ^b   Nagayoshi, R ^a   Nakamura, M ^a   Matsuda, T ^c   Hogger, P ^d   Guyre, P M ^e   Nagase, H ^b   Matsuyama, T ^a  

^a KAGOSHIMA UNIVERSITY   (Japan)

^b IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

^c Kagoshima Red Cross Hospital   (Japan)

^d UNIVERSITY OF WÜRZBURG   (Germany)

^e DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

Rheumatoid arthritis; Soluble CD163; TIMP 3

Indexed keywords

ANTIGEN; BUCILLAMINE; CD163 ANTIGEN; GOLD SALT; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLAMINE; PREDNISONE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TISSUE INHIBITOR OF METALLOPROTEINASE 3; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CELL CULTURE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ENZYME IMMUNOASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MACROPHAGE ACTIVATION; MALE; MONOCYTE; PRIORITY JOURNAL; REGULATORY MECHANISM; RHEUMATOID ARTHRITIS; SYNOVITIS; WESTERN BLOTTING;

ADULT; AGED; ANIMALS; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; ARTHRITIS, RHEUMATOID; AUTOIMMUNE DISEASES; BIOLOGICAL MARKERS; CELL LINE; DEXAMETHASONE; FEMALE; HUMANS; MACROPHAGES; MALE; MIDDLE AGED; RECEPTORS, CELL SURFACE; RECOMBINANT FUSION PROTEINS; SOLUBILITY; SPODOPTERA; SYNOVIAL FLUID; TISSUE INHIBITOR OF METALLOPROTEINASE-3; TRANSFECTION;

EID: 18544371503     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.2002.01963.x     Document Type: Article

References (31)

1. Law SKA, Micklem KJ, Shaw JM et al. A new macrophage differentiation antigen which is a member of the scavenger receptor superfamily. Eur J Immunol 1993; 23:2320-51.
2. Hogger P, Dreier J, Droste A, Buck F, Sorg C. Identification of the integral membrane protein RM3/1 on human monocytes as a glucocorticoid-inducible member of the scavenger receptor cysteine-rich family (CD163). J Immunol 1998; 161:1891-900.
3. Sulahian TH, Hogger P, Wahner AE et al. Human monocytes express CD163, which is upregulated by IL-10 and identical to p155. Cytokine 2000; 12:1312-21.
4. Ritter M, Buechler C, Langmann T, Schmitz G. Genomic organization and chromosomal localization of the human CD163 (M130) gene: a member of the scavenger receptor cystein-rich superfamily. Biochem Biophys Res Commun 1999; 260:466-74.
5. Kristiansen M, Graversen JH, Jacobsen C et al. Identification of the haemoglobin scavenger receptor. Nature 2001; 409:198-201.
6. Van den Heuvel MM, Tensen CP, van As JH et al. Regulation of CD163 on human macrophages: cross-linking of CD163 induces signaling and activation. J Leukoc Biol 1999; 66:858-66.
7. Ritter M, Buechler C, Kapinsky M, Schmitz G. Interaction of CD163 with the regulatory subunit of casein kinaseII (CKII) and dependence of CD163 signalling on CKII and protein kinase C. Eur J Immunol 2001; 31:999-1009.
8. Hamann W, Floter A, Schmultzler W, Zwadlo-Klarwasser G. Characterization of a novel anti-inflammatory factor produced by RM3/1 macrophages derived from glucocorticoid treated human monocytes. Inflam Res 1995; 44:535-40.
9. Hogger P, Sorg C. Soluble CD163 inhibits phorbol ester-induced lymphocyte proliferation. Biochem Biophys Res Commun 2001; 288:841-3.
10. Droste A, Sorg C, Hogger P. Shedding of CD163, a novel regulatory mechanism for a member of the scavenger receptor cystein-rich family. Biochem Biophys Res Commun 1999; 256:110-3.
11. Sulahian TH, Hintz KA, Wardwell K, Guyre PM. Development of an ELISA to measure soluble CD163 in biological fluids. J Immunol Meth 2001; 252:25-31.
12. Moller HJ, Peterslund NA, Graversen JH, Moestrup SK. Identification of the hemoglobin scavenger receptor/CD163 as a natural soluble protein in plasma. Blood 2002; 99:378-80.
13. Bulherin D, Fitzgerald O, Bresnihan B. Synovial tissue macrophage population and articular damage in rheumatoid arthritis. Arthritis Rheum 1996; 39:115-241.
14. Matsuyama T, Yamada A, Kay J et al. Activation of CD4 cells by fibronectin and anti-CD3 antibody: a synergic effect mediated by the VLA-5 fibronectin receptor complex. J Exp Med 1989; 170:1133-48.
15. Arnett FC, Edworthy SM, Bloch DA et al. The American rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis. Athritis Rheum 1987; 31:315-24.
16. Matsuyama T, Nakashima N, Matsuda T, Nakamura H, Uchida S, Abe T. Induction of multinucleated giant cells from rheumatoid arthritis (RA) synovial adherent cells by anti-DR antibody. Clin Exp Immunol 1994; 98:257-63.
17. Kashiwagi M, Tortorella M, Nagase H, Brew K. TIMP-3 is a potent inhibitor of aggrecanase 1 (ADAM-TS4) and aggrecanase 2 (ADAM-TS5). J Biol Chem 2001; 276:12501-4.
18. Yu S, Nakashima N, Xu BH et al. Pathological significance of elevated soluble CD14 production in rheumatoid arthritis: in the presence of soluble CD14, lipopolysaccharides at low concentrations activate RA synovial fibroblasts. Rheumatol Int 1998; 17:237-43.
19. Bodolato R, Oppenheim JJ. Role of cytokines, acute phase proteins, and chemokines in the progression of rheumatoid arthritis. Semin Arthritis Rheum 1996; 26:526-38.
20. Horneff G, Sack U, Kalden JR, Emmrich F, Burmester GR. Reduction of monocyte-macrophage activation markers upon anti-CD4 treatment. Decreased levels of IL-1, IL-6, neopterin and soluble CD14 in patients with rheumatoid arthritis. Clin Exp Immunol 1993; 91:207-131.
21. Ohshima S, Saeki Y, Mima T et al. Long-term follow-up of the changes in circulating cytokines, soluble cytokine receptors, and white blood cell subset counts in patients with rheumatoid arthritis (RA) after monoclonal anti-TNF alpha antibody therapy. J Clin Immunol 1999;19(5):305-13.
22. Charles P, Elliott MJ, Davis D et al. Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis. J Immunol 1999; 163:1521-8.
23. Torsteinsdottir I, Hakansson L, Hallgren R et al. Serum lysozyme: a potential marker of monocyte/macrophage activity in rheumatoid arthritis. Rheumatology 1999; 38:1249-54.
24. Frosch M, Strey A, Vogel T et al. Myeloid-related proteins 8 and 14 are specifically secreted during interaction of phagocytes and activated endothelium and are useful markers for monitoring disease activity in pauciarticular-onset juvenile rheumatoid arthritis. Arthritis Rheum 2000; 43:628-37.
25. Hooper NM, Turner AJ. Membrane protein secretases. Biochem Soc Trans 1999; 27:211-57.
26. Smith MR, Kung H, Durum SK, Colburn NH, Sun Y. TIMP-3 induces cell death by stabilizing TNF-alpha receptors on the surface of human colon carcinoma cells. Cytokine 1997; 9:770-80.
27. Borland G, Murphy G, Ager A. Tissue inhibitor of metalloproteinases-3 inhibits shedding of L-selectin from leukocytes. J Biol Chem 1999; 274:2810-5.
28. Hargreaves PG, Wang F, Antcliff J et al. Human myeloma cells shed the interleukin-6 receptor: inhibition by tissue inhibitor of metalloproteinase-3 and a hydroxamate-based metalloproteinase inhibitor. Br J Haematol 1998; 101:694-702.
29. Fitzgerald ML, Wang Z, Park PW, Murphy G, Bernfield M. Shedding of syndecan-1 and-4 ectodomains is regulated by multiple signaling pathways and mediated by a TIMP-3 sensitive metalloproteinase. J Cell Biol 2000; 148:811-24.
30. Takizawa M, Ohuchi E, Yamanaka H et al. Production of tissue inhibitor of metalloproteinases 3 is selectively enhanced by calcium pentosan polysulfate in human rheumatoid synovial fibroblasts. Arthritis Rheum 2000; 43:812-20.
31. Fabunmi RP, Baker AH, Murray EJ, Booth RF, Newby AC. Divergent regulation by growth factors and cytokines of 95kDa and 72kDa gelatinase and tissue inhibitors of metalloproteinase-1, -2, and -3 in rabbit aortic smooth muscle cells. Biochem J 1996; 315:335-42.